FIG. 3.

Cross talk between TLRs and PARs. Human PBMCs were treated with LPS (A), Pam3Cys (B), and β-glucan (C) in a dose-dependent manner, in combination with RPMI medium, PAR1 agonist (PAR1-AP) (TFLLR), or PAR2-AP (SLIGRL), respectively. Supernatants were collected for TNF, IL-6, and IL-8 measurements after 24 h of stimulation. The data are cumulative results of three duplicate data from 6 different donors and are expressed as means ± SE (*, P < 0.05 compared to PBMCs stimulated with LPS alone).